Towfik Sebai, MD

Indiana University Urology is seeking stage I nonseminoma survivors, 18+ years old and located in the U.S. to participate in a research study. For more information about the project 👉 testicularcancersociety.org/blogs/news/par… Thanks for your consideration. #testicularcancer #tscsm

April marks the start of Testicular Cancer Awareness Month 💜 This month is dedicated to raising awareness, encouraging early detection, and supporting those affected. Knowing your body and doing regular self-exams can make a life-saving difference. Please share this post to help spread awareness and visit our website to learn how you can get involved this April. Awareness and early detection are key! …sticularcancerawarenessfoundation.org/tc-awareness-m… #testicularcancer #urlogy

Ethan found a lump weeks before championships—but still competed. After surgery, recurrence, and chemo, he’s cancer-free. Now a Coast Guard rescue swimmer, he advocates for others to get checked. Hear his story next week! #TesticularCancerAwareness @ClintCaryMD @AggieSwimDive

I review the statistics in ~200 manuscripts a year for some of the top urology journals in the world. Here's what I actually do — and the mistakes I see in almost every paper. 🧵

@riwa_nk Congratulations!

We matched at IU!!! @RileyChildrens @IUIntMed Grateful for all the mentorship I've received from @AUB_Lebanon @InstituteStarzl. Excited to take care of your little ones!🧸 #Match2026 #CoupleMatch

Honored to share insights on surveillance after complete response to 1L chemotherapy in NSGCT (presented at ASCO GU 2026) @nabiladra. Thank you @VuMedi for the opportunity! Watch here: vumedi.com/video/ascor-gu… #Oncology #TesticularCancer #ASCOGU

Thank you @VuMedi for the opportunity to discuss our work on progression after 1L chemotherapy with normal tumor markers in NSGCT (presented at ASCO GU 2026) @nabiladra. Watch here: vumedi.com/video/ascor-gu… #Oncology #TesticularCancer #ASCOGU

@MAlAbbas97 @ZakhariaYousef Congratulations Mousab! Best of luck in your new journey.

Glad to announce that I matched into internal medicine at @UofSouthAlabama. Thanks to our mentors @IrbazRiaz @ZakhariaYousef for the unconditional support during the process. #Match2026

@jad_zeitoun Congratulations Jad! They couldn't be luckier.

Grateful and excited to share that I matched into Internal Medicine @MethodistHosp and will be staying in Houston! Thankful to my mentors, family, and friends for the constant support. Looking forward to the journey ahead 🙏🏼 #Match2026 #InternalMedicine

@NeenaSAbrahamMD @dunleavy_katie @cjketc2 @SheilaRustgiMD @YeeHuiYeo1 @RobHuangMD @LaurenNephewMD @ASGEendoscopy @KiraNewmanMDPhD @bkocharmd @EduardoVilarGo1 @IrisWangMD @MollyKellyGoss @HyderSaidMD @SonuIrene Resident Clinical Research Award: Tarek G. Aridi, MD | @TarekAridiMD Indiana University The CarePal Study: Establishing a Digital Health Approach to Real-time Monitoring of Patient Reported Needs and Outcomes in Cirrhosis Care

Exhilarating feeling seeing all my @AUB_FM classmates matching in their top choices! Congratulations to all who matched 🤍! And for those who didn’t, I hope it will all work out for the best eventually💪

@SamiSamaanMD Congratulations Sami!!!

Matched! Grateful for everyone who believed in me. The journey continues. #Match2026

Dr. Hristos Kaimakliotis spoke with @UroToday about the KEYNOTE-905 trial, which studies new treatment options for bladder cancer patients who are not eligible for cisplatin. Watch here! 👇 urotoday.com/video-lectures… #BladderCancer #KEYNOTE905 #IUUrology

It takes a remarkable team that is laser focused on patients and improving results and outcomes. Honored to be a part of the IU/IU Health group that cares for men with testicular cancer❤️ iuhealth.org/thrive/how-iu-…

Prognostic Utility of LDH in Seminoma @JenniferKingMD @IUCancerCenter @TestesCancer @TCSociety #GU26

Surveillance after complete response to frontline chemotherapy remains standard with excellent outcomes in patients with metastatic non-seminomatous GCT @TowfikSebai @IUCancerCenter @TestesCancer @TCSociety #GU26

Randomized phase2 trial of maintenance oral etoposide vs surveillance post high-dose chemo and transplant. Look forward to sharing results in near future. @TowfikSebai @IUCancerCenter @TestesCancer @TCSociety

@TowfikSebai presents findings on progression after first-line chemotherapy with normal serum tumor markers in nom-seminomatous GCT. A meaningful subset of relapsed patients can progress despite normal STMs. @IUCancerCenter @TestesCancer @TCSociety

Honored to present our study from @MDAndersonNews at ASCO GU’26 looking at the differential timing of adverse events with frontline EVP and correlation with overall survival. Grateful for the wonderful mentorship under @OAlhalabiMD @DocMattCampbell @CYJiangMD #ASCOGU2026

Thank you Drs. @nabiladra and @SalousTareq for your mentorship on this. Excited to see this project come along!